New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
19:37 EDTBCRC.R. Bard receives favorable recommendation from FDA panel for Lutonix DCB
C. R. Bard announced that the FDA Circulatory System Devices Advisory Panel provided a unanimous favorable recommendation to FDA for use of the Lutonix Drug Coated Balloon PTA Catheter, or DCB, in the U.S. The Lutonix DCB is currently under review by FDA for improving luminal diameter and reducing the incidence of restenosis for the treatment of obstructive de novo or non-stented restenotic lesions in native femoropopliteal arteries with reference vessel diameters of 4 mm to 6 mm. If approved, it is expected that the Lutonix DCB will be the first and only FDA-approved DCB available in the U.S.
News For BCR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
17:59 EDTBCRC.R. Bard sees FY15 EPS ex-items $8.95-$9.05, consensus 9.22
Subscribe for More Information
17:54 EDTBCRC.R. Bard sees Q1 EPS $2.04-$2.08, consensus $2.13
Sees Q1 sales growth 4%-5%. Guidance provided in Q4 earnings conference call.
16:16 EDTBCRC.R. Bard reports Q4 adjusted EPS $2.29, consensus $2.24
Subscribe for More Information
15:37 EDTBCRNotable companies reporting after market close
Subscribe for More Information
January 20, 2015
06:32 EDTBCRC.R. Bard upgraded to Neutral from Underweight at JPMorgan
JPMorgan upgraded C.R. Bard to Neutral on expectations drug-coated balloons growth in the U.S. is likely to exceed consensus expectations. The firm raised its price target for shares to $178 from $162.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use